It is imperative for neurologists, neurosurgeons, and neurointensivists to know how to stop life-threatening hemorrhage in both surgical and non-surgical patients. However, knowing how to medically correct a coagulopathy has become increasingly challenging as more contemporary and sophisticated anticoagulation agents are developed and prescribed. In a time sensitive and life-threatening situation, where there is little margin for error, the neurosurgeon may not have ready access to information about the drug or condition that caused the coagulopathy nor the information on how to treat it. This thorough review of the literature provides a comprehensive overview of the medications and conditions that can lead to persistent and/or life-threatening intracranial hemorrhage.
Introduction
Recognizing the vital anatomy inherent to the central nervous system, one could argue that neurologists and neurosurgeons, above any other medical subspecialists, need to understand how to effectively stop life-threatening hemorrhage. That said, knowing how to medically correct a coagulopathy has become increasingly challenging as more contemporary and sophisticated anticoagulation agents are developed and prescribed.
These newer agents not only broaden the fund of knowledge required to treat these patients but they also make it more difficult to achieve an effective reversal with each new generation of drugs that arrives on the market. When faced with a life-threatening coagulopathy, neurosurgeon and neurologist may not have ready access to information about the drug or condition that caused the coagulopathy nor the information on how to treat it.
This technical note is a comprehensive overview of the medications and conditions that can lead to persistent (or initiation of) life-threatening intracranial hemorrhage. It is compiled into 9 tables that are organized by the mechanism of coagulopathy. It documents a) the duration of action of the offending agent or condition, b) the treatment, c) the half-life of the treatment, and d) the labs needed (if available) to follow the reversal of the coagulopathy. By design, the text has been kept to a minimum and the tables made succinct in order to most practically present the relevant information. 
Methods
A comprehensive review of the literature including a pub med search from 1966 -April 2014and a Google scholar search was performed and pertinent articles were reviewed and cited. Additional information from online medical sources were reviewed and cited as well.
Results
The tables provided review key information about the medical conditions and drugs used to cause various coagulopathies. Reversal agent options are specifically named and their half-lives are reported (for patients presumed to be without end organ failure).
 Doses of reversal agents are for adult patients.
 The agents are also listed in order of preference.
 Pediatric patient data was not compiled in these tables.
 Associated labs that may be useful are listed as well.
 The levels of evidence offered are based upon the University of Wisconsin Health Care (UWHC) Guidelines which follow the criteria used by the American College of Cardiology and American Heart Association (ACC/AHA). Table 1 . This table reviews those agents that indirectly affect thrombin (generally through antithrombin) and include drugs such as the heparinoids and their reversal agents 3, 5 .
Heparin will potentiate the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin. Therefore, thrombosis is blocked through the inactivation of activated Factor X and inhibition of prothrombin's conversion to thrombin. Unfractionated heparin binds to antithrombin III (ATIII) at the site of the native pentasaccharide sequence changing its conformation and converting it from a slow to a rapid inactivator of several coagulation factors, particularly factor Xa. However, in order to inactivate thrombin, heparin must bind to thrombin and AT simultaneously, an effect that occurs only when the molecule exceeds 18 monosaccharide units (greater than 6000 daltons). Low molecular weight heparins (LMWH's) have a similar mechanism of action of heparin and retain the ability to inactivate factor Xa. However, because they are smaller molecules they cannot simultaneously bind to thrombin and AT and therefore have a lesser effect on thrombin.
Fondaparinux causes an antithrombin III-mediated selective inhibition of only factor Xa but cannot inactivate thrombin because of its extremely short length. It contains only a sulfated pentasaccharide unit with higher antithrombin affinity than the native pentasaccharide seen with unfractionated heparin.
The recommended lab work to assess efficacy of each of these agents is as follows: aPTT and/or ACT to measure heparin activity and anti-factor Xa +/-ACT to assess LMWH and Fondaparinux activity. Protamine is the most commonly recommended reversal agent for heparin and LMWH. That said Protamine has not been shown to be successful in reversing Fondaparinux. In severe cases one could consider also giving Factor VIIa in an attempt to reverse severe bleeding after administration of Fondaparinux 21 . Table 2 This table lists the newest class of anticoagulants, the direct Factor Xa inhibitors 3, 4 .
They differ from the agents in Table 1 in that they do not require a co-factor (e.g. ATIII) for activity and are considered direct Factor Xa inhibitors. While some practitioners will Table 3 reviews those agents that directly impact thrombin and include some of the newer drugs such as dabigatran 1, 3, 4, 10 . There are no antidotes to these drugs at this time but some are under development. There is also no reliable laboratory test to directly measure the extent of anticoagulation. Until such antidotes become available 4-factor PCC's and 3-factor PCC's are recommended as an effective treatment strategy (although admittedly the literature has some variation depending on the specific direct thrombin inhibitor was used 12,4 ). Some have advocated for the use of activated charcoal if the patient recently took a dose of the medication 23 . Another agent, Factor Eight Inhibitor Bypassing Activity (FEIBA) has been shown to be effective in human plasma ex vivo 13, 19 . Factor VII has been shown to be less effective as a management option 14, 20 . In addition, as the agents are partially protein bound, one could consider dialysis in patients that have renal impairment. Table 6 shows those coagulopathies that are related to platelet dysfunction due to medications 2, 3, 8, 11 . Note that the labs listed may be of limited value due to the inherent differences in results between individual patients. Also note that fish oil is not listed because the exact mechanism of action is not entirely known. It is generally thought to also be based on the clearance of fish oil from the body -which is not known 6 . A commonly employed, and supported, treatment strategy used with several antiplatelet agents is platelet transfusion 16 . This is certainly the case for NSAID's, aspirin, and clopidogrel, prasugal, abciximab, cilostazol, and aggrenox. Admittedly, this is an area of active investigation for two reasons: 1) lab work to measure the extent of anti-platelet activity is notoriously inaccurate, and 2) the need for reversal for minor cases has not been validated (nor has the efficacy). However, it is typically agreed that in severe cases of bleeding it is prudent to administer platelet transfusion. In addition, many practitioners will give DDAVP in addition to platelet transfusion if a procedure is imminent. Antiplatelet agents that may respond to reversal strategies other than platelet transfusion include: ticlopidine (can use methylprednisolone) and dipyridamole (where aminophylline may work). Table 7 shows those coagulopathies that are related to platelet dysfunction from maldevelopment or acquired deficiencies on platelet function 3, 6, 9 . The majority of these conditions respond to platelet transfusion with the exception of uremia/renal failure which may require dialysis, cryoprecipitate, or desmopressin. It is also worth noting that there is no standardization when it comes to terminology surrounding platelet transfusion and dosage administered. In this paper, a "dose" is typically 6 random donor platelet's (aka a "six pack")/ Table 8 shows the occasional scenario where an immune-related factor inhibitor is present in the blood 3, 6 . This type of coagulopathy is often associated with an elevated aPTT. In such clinical cases, it is unlikely that a specific inhibitor will be identified in a timely matter.
In addition, it is unlikely that a specific antidote will be available. Therefore, reversal strategies are broad in scope in hopes of controlling acute bleeding. At this point in time, PCC's are the favored agent. One could also consider Factor VII, aminocaproic acid or tranexamic acid. Reversal strategies for inhibitor related coagulopathies can be augmented with steroids, IVIG or plasmapheresis if severe. That said, if a specific factor specific inhibitor can be identified, it may be possible to give that specific factor when developing a reversal strategy. Table 9 differs from table 8 in that the factor is inherently absent or inadequate in function rather than being blocked by an inhibitor. 3, 6, 7 In Von Willibrand's Disease, the best treatment options include desmopressin (not in acute hemorrhage), PCC, or Factor VII. In Pseudo-Von Willibrand's Disease platelet transfusion is recommended. In cases of low fibrinogen or Factor XIII, cryoprecipitate is the recommended reversal agent. Lastly, Factor VII was specifically created for use in Hemophilia A while Factor IX Concentrate can be given in Hemophilia B (or PCC if not available).
Discussion
The included tables propose succinct and pertinent information intended to allow physicians a quick reference in order to develop a reversal strategy for a given coagulopathy. Each table lists potential reversal agents in order of preference. For 3-factor concentrates have much less factor VII. In addition, each PCC can have subtle variations in the relative concentrations of each cofactor present in the drug. It should now be clear that understanding exactly which PCC is available within a particular institution is vital to optimize treatment strategies. . Lastly, the clinician should be aware that many of the reversal agents, such as Factor VIIa and PCC can cause thrombosis and other adverse reactions (e.g. in the case of protamine, it is actual an anticoagulant at higher doses). 
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Non-septic, non-thrombotic chronic DIC (promyelocytic leukemia etc.) -note use of fibrinolysis inhibitors for reversal in acute DIC can be fatal and is not recommended.
n/a n/a Maybe Amicar (aminocaproic acid) or 4 -5 g load followed by 1 g/hr infusion. 
